Evommune(EVMN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EVMN Evommune

交易中 02-27 10:12:31 EST

26.11

-0.52

-1.95%

最高27.60	最低25.27	成交量9.57万
今开27.27	昨收26.63	日振幅8.75%
总市值8.23亿	流通市值2.45亿	总股本3,152万
成交额249.15万	换手率1.02%	流通股本940.00万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":26.11,"timestamp":1772205137379,"preClose":26.63,"halted":0,"volume":95735,"delay":0,"changeRate":-0.019526849417949667,"floatShares":9400000,"shares":31524093,"eps":-1.993,"marketStatus":"交易中","change":-0.52,"latestTime":"02-27 10:12:31 EST","open":27.27,"high":27.6,"low":25.27,"amount":2491454.35868,"amplitude":0.087495,"askPrice":26.7,"askSize":100,"bidPrice":25.8,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-1.993,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772226000000},"marketStatusCode":2,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":26.63,"preHourTrading":{"tag":"盘前","latestPrice":27.01,"preClose":26.63,"latestTime":"09:26 EST","volume":1121,"amount":30389.852632,"timestamp":1772202394750,"change":0.38,"changeRate":0.01427,"amplitude":0.057454},"postHourTrading":{"tag":"盘后","latestPrice":26.99,"preClose":26.63,"latestTime":"19:50 EST","volume":874,"amount":23873.49,"timestamp":1772153404997,"change":0.36,"changeRate":0.013519,"amplitude":0.013519},"volumeRatio":1.921546},"requestUrl":"/m/hq/s/EVMN/wiki","defaultTab":"wiki","newsList":[{"id":"2612019442","title":"Evommune, Inc.盘中异动 急速下跌5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612019442","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612019442?lang=zh_cn&edition=full","pubTime":"2026-02-18 03:28","pubTimestamp":1771356532,"startTime":"0","endTime":"0","summary":"北京时间2026年02月18日03时28分，Evommune, Inc.股票出现异动，股价快速跳水5.23%。Evommune, Inc.股票所在的生物技术行业中，整体涨幅为0.49%。其相关个股中，Polaryx Therapeutics, Inc.、Cibus, Inc.、Biodexa Pharmaceuticals Plc涨幅较大，Ensysce Biosciences, Inc.、Polaryx Therapeutics, Inc.、Ernexa Therapeutics Inc.较为活跃，换手率分别为810.90%、101.69%、96.36%，振幅较大的相关个股有Polaryx Therapeutics, Inc.、Ensysce Biosciences, Inc.、Liminatus Pharma Inc C/Wts 30/04/2030 ，振幅分别为81.33%、74.28%、39.89%。Evommune, Inc.公司简介：Evommune Inc 是一家临床阶段的生物技术公司，专注于开发针对慢性炎症性疾病关键驱动因素的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218032852a4ae1699&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218032852a4ae1699&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EVMN","BK4139"],"gpt_icon":0},{"id":"2611901796","title":"Evommune, Inc.盘中异动 大幅跳水5.09%报27.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611901796","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611901796?lang=zh_cn&edition=full","pubTime":"2026-02-12 22:32","pubTimestamp":1770906774,"startTime":"0","endTime":"0","summary":"北京时间2026年02月12日22时32分，Evommune, Inc.股票出现波动，股价快速跳水5.09%。截至发稿，该股报27.01美元/股，成交量2.4506万股，换手率0.08%，振幅2.16%。Evommune, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Evommune, Inc.公司简介：Evommune Inc 是一家临床阶段的生物技术公司，专注于开发针对慢性炎症性疾病关键驱动因素的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223254a49ce8d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223254a49ce8d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EVMN"],"gpt_icon":0},{"id":"1168920254","title":"Evommune公司：同时评估Evo301的潜在新增适应症，包括溃疡性结肠炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1168920254","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168920254?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:32","pubTimestamp":1770726755,"startTime":"0","endTime":"0","summary":"Evommune公司正在对Evo301的潜在新增适应症展开评估，其中溃疡性结肠炎是重点考察方向之一。这一举措旨在拓宽该药物的应用范围，为更多患者提供治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"gpt_icon":0},{"id":"1100113507","title":"Evommune公布Evo301治疗中重度特应性皮炎二期a期概念验证试验积极顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1100113507","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100113507?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:31","pubTimestamp":1770726682,"startTime":"0","endTime":"0","summary":"生物制药公司Evommune近日宣布，其研发的候选药物Evo301在中重度特应性皮炎患者中开展的二期a期概念验证试验获得积极顶线结果。\n该试验数据表明Evo301在主要疗效终点上表现出显著改善，验证了其治疗潜力。这项突破为后续临床开发奠定了坚实基础，有望为特应性皮炎患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"gpt_icon":0},{"id":"1101351099","title":"Evommune首次公开募股定价为每股16美元，发行937.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1101351099","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101351099?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:46","pubTimestamp":1763570777,"startTime":"0","endTime":"0","summary":"11月5日 - Evommune Inc 公告：*Evommune宣布首次公开募股定价* Evommune Inc - 首次公开募股定价为每股16美元，共发行937.5万股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"gpt_icon":0},{"id":"2581015296","title":"美股异动 | 生物医药公司Evommune(EVMN.US)登陆美股市场 股价涨超15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581015296","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581015296?lang=zh_cn&edition=full","pubTime":"2025-11-07 00:00","pubTimestamp":1762444800,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Evommune(EVMN.US)登陆美股市场，截至发稿，该股涨超15%，报18.38美元，IPO价格为16美元。Evommune 是一家临床阶段的生物医药公司，其使命是通过创新疗法，治疗 “免疫介导的慢性炎症性疾病”。这类疾病包括慢性荨麻疹、特应性皮炎、其他与肥大细胞/炎症相关的病症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EVMN","161726","399441"],"gpt_icon":0},{"id":"2576361788","title":"慢性炎症性疾病生物科技公司Evommune(EVMN.US)IPO定价15-17美元/股 拟筹资1.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576361788","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576361788?lang=zh_cn&edition=full","pubTime":"2025-10-20 15:54","pubTimestamp":1760946879,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注研发慢性炎症性疾病疗法的二期临床阶段生物科技公司Evommune于上周五公布了其首次公开募股的发行条款。公司计划通过发行940万股股票筹集1.5亿美元，发行价区间设定为15至17美元。若按发行价区间中值计算，Evommune的市值将达到5.43亿美元。该药物已启动2b期临床试验，预计于2026年下半年公布结果。由于美国政府持续停摆，Evommune未依赖美国证券交易委员会宣布其注册声明生效。公司预计于2025年11月3日当周确定最终发行价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EVMN","159837"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.evommune.com","stockEarnings":[{"period":"1week","weight":-0.0731},{"period":"1month","weight":0.3587},{"period":"3month","weight":0.2859},{"period":"6month","weight":0.6644},{"period":"ytd","weight":0.5555}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Evommune, Inc.是一家于2020年4月在特拉华州注册成立的公司，总部位于加利福尼亚州的帕洛阿尔托。该公司是一家临床阶段的生物技术公司，专注于针对慢性炎症疾病主要致病因素的创新治疗方案开发。其初步临床开发项目集中在慢性自发性荨麻疹、特应性皮炎和溃疡性结肠炎上。","exchange":"NYSE","name":"Evommune","nameEN":"Evommune"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Evommune(EVMN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Evommune(EVMN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Evommune,EVMN,Evommune股票,Evommune股票老虎,Evommune股票老虎国际,Evommune行情,Evommune股票行情,Evommune股价,Evommune股市,Evommune股票价格,Evommune股票交易,Evommune股票购买,Evommune股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Evommune(EVMN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Evommune(EVMN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}